RIMEGEPANT AS A NOVEL THERAPEUTIC OPTION FOR MIGRAINE: A SYSTEMATIC REVIEW OF SAFETY AND TOLERABILITY

Weronika Zarzycka; Jakub Skrzypek; Natalia Fidut; Karol Szyprowski; Kamila Zioło; Maciej  Kisielewski; Julia Wawerska; Weronika Wrzosek; Mateusz Zugaj; Bartosz Okliński

doi:10.31435/ijitss.1(49).2026.5290

Authors

Weronika Zarzycka 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0009-0004-1927-4076
Jakub Skrzypek Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0004-1155-5818
Natalia Fidut Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0006-2550-3933
Karol Szyprowski 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0009-0001-0336-6425
Kamila Zioło 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0009-0003-3875-4000
Maciej Kisielewski Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0003-1797-9155
Julia Wawerska Medical University of Lodz, Łódź, Poland https://orcid.org/0009-0006-0145-6204
Weronika Wrzosek University Clinical Hospital No. 1 in Lublin, Lublin, Poland https://orcid.org/0009-0002-6680-5760
Mateusz Zugaj Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0000-2848-6952
Bartosz Okliński Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0003-9018-6784

DOI:

https://doi.org/10.31435/ijitss.1(49).2026.5290

Keywords:

Migraine, Rimegepant, Treatment, Safety, Adverse Events

Abstract

Objective. The aim of this paper is to analyze and evaluate currently available data and studies on the safety and tolerability of rimegepant in the treatment of migraine.

Methodology. This literature review was based on articles from 2019–2026 available on PubMed and Google Scholar, including randomized controlled trials, open-label studies, and meta-analyses.

Findings. Adverse reactions to rimegepant observed in clinical trials are largely mild or moderate. Serious adverse reactions and those leading to treatment discontinuation are rare and often considered unrelated to the drug. The most frequently reported adverse events in the databases were related to “general disorders and administration site conditions”. Rimegepant is safe for patients with high cardiovascular risk and no hepatotoxicity associated with this drug is observed. Compared to other available therapies, rimegepant also ranks highly in terms of both efficacy and safety.

Conclusion. Rimegepant is a safe and well-tolerated oral medication for both acute and preventative migraine treatment. It is also a good alternative to other poorly tolerated or contraindicated migraine drugs.

References

Antinew, J., Fountaine, R. J., Loprinzo, V., Straghan, E., Dubrovin, S., DeBesi, P., Vatakis, N., & Fullerton, T. (2025). A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention. The Journal of Headache and Pain, 27(1), 17. https://doi.org/10.1186/s10194-025-02225-7

Croop, R., Berman, G., Kudrow, D., Mullin, K., Thiry, A., Lovegren, M., L’Italien, G., & Lipton, R. B. (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia, 44(4), 3331024241232944. https://doi.org/10.1177/03331024241232944

de Vries, T., Al-Hassany, L., & MaassenVanDenBrink, A. (2021). Evaluating rimegepant for the treatment of migraine. Expert Opinion on Pharmacotherapy, 22(8), 973–979. https://doi.org/10.1080/14656566.2021.1895749

Deng, X., Zhou, L., Liang, C., Shang, X., Hui, X., Liu, W., Liang, S., Wang, Y., Xu, M., Guo, K., Yang, K., & Li, X. (2024). Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: Systematic review and network meta-analysis of randomised trials. The Journal of Headache and Pain, 25(1), 16. https://doi.org/10.1186/s10194-024-01723-4

Edvinsson, L. (2024). Rimegepant for the acute and preventive treatment of migraine: A narrative review of the evidence. Expert Review of Neurotherapeutics, 24(12), 1141–1155. https://doi.org/10.1080/14737175.2024.2434079

GBD 2023 Headache Collaborators. (2025). Global, regional, and national burden of headache disorders, 1990–2023: A systematic analysis for the Global Burden of Disease Study 2023. The Lancet Neurology, 24(12), 1005–1015. https://doi.org/10.1016/S1474-4422(25)00402-8

Iannone, L. F., Vaghi, G., Sebastianelli, G., Casillo, F., Russo, A., Silvestro, M., Pistoia, F., Volta, G. D., Cortinovis, M., Chiarugi, A., Montisano, D. A., Prudenzano, M. P., Cevoli, S., Mampreso, E., Avino, G., Romozzi, M., Valente, M., Fasano, C., Battistini, S., … Italian Headache Registry (RICe) Study Group. (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: A real-world, prospective, multicentric study (GAINER study). The Journal of Headache and Pain, 26(1), 4. https://doi.org/10.1186/s10194-024-01935-8

Ikeda, K., Matsumori, Y., Kudo, M., Ishikawa, T., Hoshino, Y., Yoshimatsu, H., Thiry, A., Arakawa, A., Croop, R., Fullerton, T., Sakai, F., & Takeshima, T. (2025). Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial. Headache, 65(10), 1811–1820. https://doi.org/10.1111/head.14994

Jakubowska, B., & Sowa-Kućma, M. (2025). Gepants: Targeting the CGRP pathway for migraine relief. Frontiers in Pharmacology, 16, 1708226. https://doi.org/10.3389/fphar.2025.1708226

Johnston, K., Popoff, E., Deighton, A., Dabirvaziri, P., Harris, L., Thiry, A., Croop, R., Coric, V., L’Italien, G., & Moren, J. (2022). Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: A network meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 22(1), 155–166. https://doi.org/10.1080/14737167.2021.1945444

Kudrow, D., Croop, R. S., Thiry, A., & Lipton, R. B. (2026). A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache, 66(2), 407–416. https://doi.org/10.1111/head.15002

Kudrow, D., Hutchinson, S., Pixton, G. C., & Fullerton, T. (2025). Safety of rimegepant in adults with migraine and anxiety, depression, or using antidepressants: Analysis of a multicenter, long-term, open-label study. Pain and Therapy, 14(1), 237–255. https://doi.org/10.1007/s40122-024-00675-6

Liang, Q., Liao, X., Wu, H., Huang, Y., Liang, T., & Li, H. (2024). Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases. Frontiers in Pharmacology, 15, 1431562. https://doi.org/10.3389/fphar.2024.1431562

Lipton, R. B., Croop, R., Stock, E. G., Stock, D. A., Morris, B. A., Frost, M., Dubowchik, G. M., Conway, C. M., Coric, V., & Goadsby, P. J. (2019). Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. The New England Journal of Medicine, 381(2), 142–149. https://doi.org/10.1056/NEJMoa1811090

Lipton, R. B., Thiry, A., Morris, B. A., & Croop, R. (2024). Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: A randomized, double-blind, placebo-controlled trial. Journal of Pain Research, 17, 2431–2441. https://doi.org/10.2147/JPR.S453806

Messina, R., Huessler, E.-M., Puledda, F., Haghdoost, F., Lebedeva, E. R., & Diener, H.-C. (2023). Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia, 43(3), 3331024231152169. https://doi.org/10.1177/03331024231152169

Pozo-Rosich, P., López, J. A. G., Lisewski, P., Aslan, A. N., Seehra, H., Thiry, A., Abraham, L., Ramirez, L. M., Fountaine, R., & Fullerton, T. (2025). A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia, 45(11), 3331024251391378. https://doi.org/10.1177/03331024251391378

Puledda, F., Younis, S., Huessler, E.-M., Haghdoost, F., Lisicki, M., Goadsby, P. J., & Tassorelli, C. (2023). Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia, 43(3), 3331024231151419. https://doi.org/10.1177/03331024231151419

Schwedt, T. J., Myers Oakes, T. M., Martinez, J. M., Vargas, B. B., Pandey, H., Pearlman, E. M., Richardson, D. R., Varnado, O. J., Cobas Meyer, M., & Goadsby, P. J. (2024). Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: Results from a randomized, controlled clinical trial. Neurology and Therapy, 13(1), 85–105. https://doi.org/10.1007/s40120-023-00562-w

Tassorelli, C., Onishchenko, K., Halker Singh, R. B., Duan, M., Dupont-Benjamin, L., Hemstock, M., Voller, C., McAllister, P., Nahas, S. J., Gandhi, P., & Ailani, J. (2024). Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia, 44(2), 3331024241235156. https://doi.org/10.1177/03331024241235156

Tepper, S. J., Jenkins, A., Henriksen, C., Dai, F., Atkinson, J., Abraham, L., & Gendolla, A. (2025). A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data. Cephalalgia, 45(7), 3331024251352849. https://doi.org/10.1177/03331024251352849

True, D., Mullin, K., & Croop, R. (2024). Safety of rimegepant in adults with migraine and cardiovascular risk factors: Analysis of a multicenter, long-term, open-label study. Pain and Therapy, 13(5), 1203–1218. https://doi.org/10.1007/s40122-024-00626-1

Woodhead, J. L., Siler, S. Q., Howell, B. A., Watkins, P. B., & Conway, C. (2022). Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicological Sciences, 188(1), 108–116. https://doi.org/10.1093/toxsci/kfac051

Yang, C.-P., Liang, C.-S., Chang, C.-M., Yang, C.-C., Shih, P.-H., Yau, Y.-C., Tang, K.-T., & Wang, S.-J. (2021). Comparison of new pharmacologic agents with triptans for treatment of migraine: A systematic review and meta-analysis. JAMA Network Open, 4(10), e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544

Yang, Z., Wang, X., Niu, M., Wei, Q., Zhong, H., Li, X., Yuan, W., Xu, W., Zhu, S., Yu, S., Liu, J., Yan, J., Kang, W., & Huang, P. (2024). First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients. The Journal of Headache and Pain, 25(1), 160. https://doi.org/10.1186/s10194-024-01873-5